# FDA 483 - The Compounding PHY of Beverly Hills - August 16, 2019

Source: https://www.keypedia.com/records/483/the-compounding-phy-of-beverly-hills/492711f5-b8a5-4c69-bd13-def654b0f314

> FDA 483 for The Compounding PHY of Beverly Hills on August 16, 2019. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: The Compounding PHY of Beverly Hills
- Inspection Date: 2019-08-16
- Product Type: drugs
- Office Name: Division of Pharmaceutical Quality Operations IV
- Summary: An FDA inspection of The Compounding PHY of Beverly Hills revealed critical deficiencies in their non-sterile drug production. The firm used non-pharmaceutical grade water without quality control, lacked essential laboratory testing for components and finished products, and failed to provide employees with current good manufacturing practices (GMP) training. These findings indicate a severe absence of quality assurance in their compounding operations.

## Related Officers

- [Supervisory microbiologist](https://www.keypedia.com/people/zachery-l-miller/e7ff2001-1e81-4483-9e9b-288b7e92c719)

Company: https://www.keypedia.com/companies/the-compounding-phy-of-beverly-hills/cdaad002-7167-4b59-b6d7-b651409cf2a0

Office: https://www.keypedia.com/offices/division-of-pharmaceutical-quality-operations-iv/a2d2ff91-dc0f-433e-b91f-ca90ff8998b6